medigraphic.com
ISSN 1029-3035 (Electronic)

2013, Number S2

<< Back Next >>

Mediciego 2013; 19 (S2)

Anthracycline-induced cardiotoxicity. A case presentation

Baró RM, Sánchez GEL, García SW

Language: Spanish
References: 13
Page:
PDF size: 42.40 Kb.


ABSTRACT

A case attended in the “Dr. Antonio Luaces Iraola” Provincial Hospital of Ciego de Avila is presented, that it considers important for its little frequency. A 54-year-old woman with injury in the palate, of big size, rounded, of hard and irregular surface, to which some studies are carried out and it diagnosed to her a quite differentiated Non-Hodgkin Lymphoma. It offers chemotherapy treatment of 8 cycles every 21 days, to 7th cycle with an accumulate dose of doxorubicin 660mg/m2, begins with dyspnea to the big efforts, its clinical condition was worsening and she arrives to the Hospital with an acute pulmonary edema, clinical studies were carried out . The case is concluded with dilated cardiomyopathy diagnosis.


REFERENCES

  1. Braunwald E. Braunwald Heart Disease. 7 ed. New York: Saunders; 2005.

  2. Lipshutz S. Late cardiac efects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Eng J Med. 2003; 324:808-15.

  3. Kesevan S. Anthracycline-induced cardiotoxicity. Ann Intern Med. 2006; 125:47-58.

  4. Von Hoff D. Daunomycin-induced cardiotoxity in children and adults. Am J Med. 1997; 62:200- 8.

  5. Arsen Rl. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 2006; 70:73-77.

  6. Steinherz L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Ass. 2008; 266:1672-7.

  7. Geiger S, Lange V. Suhl P, Heinemam V, Stembler HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010: 21(6): 578-90.

  8. Shan K, Lincoff AM. Young JB. Antrathracycline induced cardiotoxicity. Ann Inter Med. 1996; 125(1): 47-58.

  9. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol [Internet]. 1991 [citado 23 Ene 2013]. 9(7): 1215-1223. Disponible en: http://jco.ascopubs.org/content/9/7/1215.short

  10. Nieto Y, Cagnoni A. Cardiac toxicity following high dose ciclophosphamide, cisptatin, and BNC (stamp-I) for breast cancer. Biol Blood Marrow Transpl. 2012; 6(2A): 198-2003.

  11. Kerkela R, Gazette l. Cardiotoxicity of the cancer therapheutic agent imatinibmesylate. Nat Med. 2006; 12(8): 908-16.

  12. Rosti G, Martinelli G. Cardiotoxiciti of the chemotherapeutic agents: incidence treatment and prevention. Drug Safety. 2011; 22:302.

  13. 13.Stemmber HJ. Anticancer therapy induced cardiotoxicity review of the literature. Anticancer Drugs. 2010; 21(6): 578-90.




2020     |     www.medigraphic.com